Payment overview · 2025
General Payments
$245.02
12 reported records · 8 companies
Healthcare provider profile · identity verified
Scott Roger Johnson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · AURORA, NE · NPI 1497761134
Verified facts
What the public records show
CMS Open Payments records show Scott Roger Johnson, M.D. received $245.02 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.98 | 27.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $37.85 | 15.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.62 | 12.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.88 | 11.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.96 | 11.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.66 | 9.2% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.95 | 6.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.12 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.02 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $66.98 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.85 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $29.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $28.88 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.96 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 588 | 91 |
| Furosemide | Furosemide | 392 | 57 |
| Losartan Potassium | Losartan Potassium | 331 | 84 |
| Gabapentin | Gabapentin | 317 | 49 |
| Omeprazole | Omeprazole | 313 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 70 |
| Potassium Chloride | Potassium Chloride | 305 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 66 |
| Lisinopril | Lisinopril | 277 | 66 |
| Metformin Hcl | Metformin Hcl | 270 | 57 |
| Tramadol Hcl | Tramadol Hcl | 267 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 26 |
| Meloxicam | Meloxicam | 146 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 14 |
| Warfarin Sodium | Warfarin Sodium | 135 | 15 |
| Carvedilol | Carvedilol | 132 | 27 |
| Montelukast Sodium | Montelukast Sodium | 132 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 131 | 28 |
| Sertraline Hcl | Sertraline Hcl | 124 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 22 |
| Simvastatin | Simvastatin | 110 | 28 |
| Famotidine | Famotidine | 104 | 12 |
| Alendronate Sodium | Alendronate Sodium | 101 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 91 | 15 |
| Allopurinol | Allopurinol | 90 | 18 |
| Eliquis | Apixaban | 77 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 71 | 11 |
| Donepezil Hcl | Donepezil Hcl | 70 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 65 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 12 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Celecoxib | Celecoxib | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Prednisone | Prednisone | 47 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 13 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 13 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Theophylline | Theophylline Anhydrous | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.02 · 12 records | ABBVIE INC. | AIRSUPRA, AVYCAZ, DALVANCE, FUROSCIX, Ozempic, PAXLOVID, REXULTI, SPRAVATO, SYMPLICITY G3, TEFLARO, UBRELVY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error